BMO Capital Maintains Market Perform on Fate Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Etzer Darout maintains a Market Perform rating on Fate Therapeutics (NASDAQ:FATE) and lowers the price target from $7 to $6.
May 10, 2024 | 3:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BMO Capital analyst Etzer Darout has maintained a Market Perform rating on Fate Therapeutics and lowered the price target from $7 to $6.
The reduction in price target by BMO Capital suggests a bearish outlook on the stock's short-term price movement. This adjustment reflects the analyst's revised expectations on the company's future performance, which could influence investor sentiment and potentially lead to a decrease in stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100